Literature DB >> 2434491

Domain mapping of chicken gizzard caldesmon.

T Fujii, M Imai, G C Rosenfeld, J Bryan.   

Abstract

Limited proteolysis, affinity chromatography, and immunoblotting have been used to define the domains of chicken gizzard caldesmon, caldesmon120, that interact with calmodulin, F-actin, and a monoclonal antibody prepared using human platelet caldesmon. Treatment of caldesmon120 with chymotrypsin produces groups of fragments near 100, 80, 60, 38, and 20 kDa. Further digestion produces peptides between 40 and 50 kDa. The 100- and 80-kDa peptides cross-react with the monoclonal antibody; the smaller polypeptides do not. The kinetics of cleavage and the antibody studies indicate that the 38- and 80-kDa fragments are the two major pieces of the 120-kDa protein. The 38-kDa fragment, purified by high performance liquid chromatography, and several of its subfragments at 21 and 25 kDa sediment with F-actin, bind to calmodulin-Sepharose in the presence of Ca2+, and are displaced from F-actin by Ca2+-calmodulin. The 80-kDa fragments did not interact with F-actin or calmodulin. We have tentatively placed the 38-kDa fragment at the C-terminal using polyclonal antibodies selected against a beta-galactosidase-caldesmon120 fusion protein produced by a lambda gt11 lysogen. The 38-, 25-, and 21-kDa fragments cross-react with these antibodies; the 80- and 60-kDa fragments do not. Caldesmon77 from human platelets also cross-reacts with these selected antibodies. The results suggest that interacting calmodulin and F-actin binding sites are localized on a 38-kDa C-terminal fragment of caldesmon. The smallest subfragment of this peptide that binds to both F-actin and calmodulin-Sepharose is about 21 kDa. The monoclonal antibody epitope is tentatively localized near the N-terminal of caldesmon77 and must be within 50 kDa of the N-terminal on caldesmon120.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434491

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  A mosaic multiple-binding model for the binding of caldesmon and myosin subfragment-1 to actin.

Authors:  Y D Chen; J M Chalovich
Journal:  Biophys J       Date:  1992-10       Impact factor: 4.033

2.  Involvement of caldesmon at the actin-myosin interface.

Authors:  M C Harricane; E Fabbrizio; C Arpin; D Mornet
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

3.  A long helix from the central region of smooth muscle caldesmon.

Authors:  C L Wang; J M Chalovich; P Graceffa; R C Lu; K Mabuchi; W F Stafford
Journal:  J Biol Chem       Date:  1991-07-25       Impact factor: 5.157

Review 4.  The molecular anatomy of caldesmon.

Authors:  S B Marston; C S Redwood
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

5.  Some properties of duck gizzard caldesmon.

Authors:  A V Vorotnikov; N B Gusev
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

6.  Mode of caldesmon binding to smooth muscle thin filament: possible projection of the amino-terminal of caldesmon from native thin filament.

Authors:  E Katayama; M Ikebe
Journal:  Biophys J       Date:  1995-06       Impact factor: 4.033

7.  Effect of unphosphorylated smooth muscle myosin on caldesmon-mediated regulation of actin filament velocity.

Authors:  K Y Horiuchi; S Chacko
Journal:  J Muscle Res Cell Motil       Date:  1995-02       Impact factor: 2.698

8.  Caldesmon and the structure of smooth muscle thin filaments: electron microscopy of isolated thin filaments.

Authors:  C Moody; W Lehman; R Craig
Journal:  J Muscle Res Cell Motil       Date:  1990-04       Impact factor: 2.698

Review 9.  Caldesmon, acidic amino acids and molecular weight determinations.

Authors:  J Bryan
Journal:  J Muscle Res Cell Motil       Date:  1989-04       Impact factor: 2.698

10.  Reversal of caldesmon binding to myosin with calcium-calmodulin or by phosphorylating caldesmon.

Authors:  M E Hemric; F W Lu; R Shrager; J Carey; J M Chalovich
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.